Objective -To review, from the purchaser's perspective, the current state of knowledge of techniques for investigation and treating coronary artery disease. The study was based on evidence from past and continuing randomised controlled trials (RCTs). Criteria for inclusion of reports -Articles listed on Medline (1990-3) with the keywords coronary disease, angina, and unstable angina (combined with surgery, economics, therapy, or drug therapy) and percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafting (CABG) were included.
Articles published before 1990 were obtained from two comprehensive literature reviews published by the Rand organisation in 199112 and from the papers obtained using the Medline search. A hand search of relevant journals published between July 1993 and June 1994 was also undertaken. Results from more recently published RCTs are included. Results -CABG provides improved angina relief compared with drug treatment and may prolong life in patients with more severe illness. PTCA is also better than drug treatment, but less so than CABG, and its cost advantages over CABG decrease with time. Repeat intervention for return of symptoms is more frequently required after PTCA, but increasing numbers ofpatients are also undergoing second and third repeat CABG for graft occlusion in the years after the original operation. Newer PTCA techniques are not, as yet, fully evaluated. One technique, atherectomy, has been shown to be no more effective, and more expensive, than conventional balloon angioplasty. In Ischaemic heart disease (IHD) is the leading cause of death in the United Kingdom and a common cause of morbidity.3 5Increasing rates of invasive procedures (coronary artery bypass grafting (CABG) and percutaneous coronary angioplasty (PTCA)) have coincided with a gradual reduction in age adjusted IHD death rates since the 1970s,6 although it seems unlikely that these procedures have played more than a minor role in the observed decline.7
Treatments for IHD consume 2-5% of NHS expenditure.8 If the current (1984) UK target of 300 CABGs per million population per year is met, the annual bill will be in excess of £60M.9 This target level has now been met in many areas and various authorities suggest that higher target levels may be appropriate.'0 In addition 8459 PTCAs (costing approximately /J3000 each) were performed in the UK in 1990."
There is striking variation in these intervention rates. ' At 2-5 years there was no significant difference between the two groups' mortality or mortality and acute myocardial infarction combined. Sixteen (3-1-%) patients in the PTCA arm and 18 (3 6%) in the CABG arm of the trial had died. CABG offered significantly better angina relief at six months (89% CABG group symptom free versus 68% in PTCA group) and at two years (78% versus 69%). In addition, 38% of those in the PTCA group had either had an acute myocardial infarction, died, or required revascularisation compared with only 11% in the CABG group (p<0001).
In EAST, the other large randomised trial which has reported medium term (three years) results, 392 patients were randomised to CABG or PTCA.33 There was no difference in mortality or the combined outcome of death, acute myocardial infarction, or the presence of large filling defects on thallium scans at three years between CABG and PTCA. Angina, however, was significantly more improved in those who underwent CABG (88% v 80% angina free), although there was no difference in exercise tolerance. Three times more ofthose treated with PTCA subsequently required repeat revascularisation.
Three other randomised trials have reported outcomes one to two years after randomisation.3>' In GABI the combination of death or acute myocardial infarction occurred more frequently in the CABG arm of the trial (13-6% v 6% p=0-017). However, four of the nine deaths in the CABG patients occurred before surgery. Forty four per cent ofthe PTCA patients required repeat revascularisation compared with only 6% of those treated with CABG.31 The other two trials showed no significant differences in mortality between CABG and PTCA. They too showed that reintervention was required considerably more frequently in those treated with PTCA. Better symptomatic relief was achieved by CABG.'0-2 A number of observational studies have also provided evidence on this matter. They have failed to show any difference in medium and long term survival between the two treatment categories although symptomatic improvement is more likely with CABG and the need for further intervention is considerably reduced. PTCA and CABG offer improved relief over medical treatment for the distress, though not necessarily the disability, caused by angina. PTCA does not offer improved survival or symptom relief over CABG. Short term costs of PTCA are lower, although it has not been shown to be more cost effective than CABG. Use ofthese procedures should be concentrated upon the more severe grades of angina unrelieved by optimum drug treatment. Within these grades there are those, who can only be identified by angiographic delineation of vessel involvement, upon whom CABG confers improved survival. Use of PTCA and CABG will therefore depend partly upon whether the primary target is improved survival or relief of distress. The "preferred outcome" for angina patients needs to be more clearly defined. Choices need to be made and a balance struck between the goals of reduced premature mortality, reduced frequency of pain and distress from angina, the probability of further intervention, and the ability to return to work. Patients should be informed of the relative benefits and disadvantages of CABG and PTCA, where either procedure is indicated, to enable them to make fully informed choices.
Under certain circumstances it seems likely that the advantages to patients of decentralised coronary angiography and PTCA services are outweighed by their disadvantages in terms of reduced quality and safety. These circumstances occur either when surgical support is beyond a reasonable distance or when only low throughput is possible. It is unlikely that operators in a district based service with a throughput below several hundred cases would be able to maintain satisfactory levels of expertise and familiarity with changing equipment. Professional bodies have produced a series of guidelines on this matter and these should generally be adhered to.
Further research is required in a number of areas. These include a pressing need for a pragmatic randomised controlled trial comparing patients with similar angina scores randomised either to receive early angiography and subsequent interventions or be managed expectantly. Further randomised controlled trials are also required to compare CABG and modem medical management of angina in those for whom CABG has not already been shown to prolong life. Finally, angiographic investigation should not be made more widely available until the indications for further intervention have been agreed and the necessary capacity to perform CABGs established. 
